| 摘要 |
Compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, L, the ring system defined by F and G, W, T, B and n are as defined herein. |
